Why is Connect Biopharma stock plunging 33% today?
Connect Biopharma's stock fell 33.6% to $1.145 after its Phase 2 asthma drug trial failed to meet the primary endpoint, despite showing some positive results. The company's drug, rademikibart, did not achieve statistical significance in reducing treatment failure rates. Analysts had previously set a $7.00 price target. The broader market also declined slightly.
How this was made
The 30-second read
Why it matters
The miss caused a 33% plunge, underscoring the volatility of early‑stage biotech trials.
Market read
The trial outcome directly drove a large intraday move, offering a clear trading signal.
What to watch
Analyst coverage and prior buy rating may have inflated expectations.
Background
Connect Biopharma announced Phase 2 results for rademikibart, missing the primary endpoint.
Ticker impact
Phase 2 asthma trial missed primary endpoint, causing a 33% share price drop.
Further downside expected if no remedial data or partnership emerges.
Clinical failure and high analyst expectations created a large gap, likely to sustain pressure.
Market effects
Highlights risk in asthma/IL‑4Rα biotech space and may pressure peers.
Limited to US biotech sector; no broader market effect.
Minimal beyond specialty pharma investors.
Counterpoint
Positive lung‑function signal could support a rebound if Phase 3 design improves.
Key entities
- CompanyConnect Biopharma Holdings Ltd
Biopharma developer of rademikibart.
- AnalystH.C. Wainwright
Maintained a Buy rating and $7 price target prior to the release.
